Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
2Q21 Reported With Updates To Clinical Trials
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Onconova Reported 2Q21 and Updated Its Clinical Trial Progress Onconova reported a net loss of $4.2 million or $(0.27) per share for 2Q21, ended June 30. Cash on hand was $43.7 million, which we project to be sufficient for operations through 2023. The company gave updates on the clinical progress for several clinical trials of its two lead products, ON123300 and rigosertib.
The ON123300 Phase 1 solid tumor study has opened enrollment of its second cohort. The first cohort has completed enrollment without dose-limiting toxicities. The ON123300 study in China is enrolling its third cohort in solid tumors, and has also not had dose-limiting toxicities. The company plans to use the data from these two trials to design the Phase 2 trial in 1H22 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.